



Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn's disease: a KASID prospective multicenter study

Kyunghwan Oh^{1*}, Hee Seung Hong^{1*}, Nam Seok Ham^{1§}, Jungbok Lee², Sang Hyoung Park^{1,3,4}, Suk-Kyun Yang^{1,3,4}, Hyuk Yoon⁵, You Sun Kim⁶, Chang Hwan Choi⁷, Byong Duk Ye^{1,3,4}, on behalf of the Korean Association for the Study of Intestinal Diseases

Departments of ¹Gastroenterology and ²Clinical Epidemiology and Biostatistics, ³Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul; ⁴Digestive Diseases Research Center, University of Ulsan College of Medicine, Seoul; ⁵Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam; ⁶Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul; ⁷Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea

<https://doi.org/10.5217/ir.2021.00173>
Intest Res 2023;21(1):137-147

In the article entitled “Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn's disease: a KASID prospective multicenter study,”¹ the data on page 140 of the text were incorrectly indicated. The revised data are shown in bold.

“Corticosteroid-free clinical remission/response were achieved in 25 (51.0%)/**29 (59.2%)** patients at week 8 and **26 (53.1%)**/34 (69.4%) patients at week 20, respectively (Fig. 2).”

REFERENCE

1. Oh K, Hong HS, Ham NS, et al. Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn's disease: a KASID prospective multicenter study. Intest Res 2023;21:137-147.